News
Public · Published
InflaRx NV expected to post a loss of 6 cents a share - Earnings Preview
InflaRx NV is expected to report a fall in quarterly revenue for the period ending September 30, 2026, with results due November 3. LSEG's mean analyst estimate is a loss of 6 cents per share.
Published:
Updated:
What happened
InflaRx NV is expected to report a fall in quarterly revenue for the period ending September 30, 2026, with results due November 3. LSEG's mean analyst estimate is a loss of 6 cents per share.
Confirmed
Global impact / market context
An expected loss means analysts think costs will exceed revenue, which can reduce cash available to fund research. For a drug developer, continued losses may increase reliance on outside funding or future share sales, which can dilute existing owners.
Analyst inference
Analysts rate the shares a buy on average, with eight buy recommendations and none to hold or sell. The median 12-month price target of $8.50 sits far above the last closing price of $1.72, suggesting analysts see large potential upside.
Analyst inference
What to watch
- The company reports results on November 3 for the quarter ending September 30, 2026, and actual figures will show whether the 6-cent loss estimate was beaten, met, or missed. Confirmed
- Watch whether management proposes spending plans, financing needs, or changes to research programs, since these choices affect future cash needs and revenue prospects. Proposed
- Compare the reported loss with the prior quarter's loss and with the unchanged estimate, as a wider loss could signal higher costs or weaker revenue than analysts expect. Analyst inference
Evidence
- Original source link unavailable